Seminars in Oncology
Volume 31, Issue 5 , Pages 595-604 , October 2004

Altered molecular pathways in gliomas: An overview of clinically relevant issues

  • Ravi D. Rao

      Affiliations

    • Department of Oncology, Division of Medical Oncology, Mayo Clinic and Foundation, Rochester, MN, USA.
    • ,
  • C. David James

      Affiliations

    • Division of Experimental Pathology, Mayo Clinic and Foundation, Rochester, MN, USA.
    • Corresponding Author InformationAddress reprint requests to C. David James, PhD, Division of Experimental Pathology, Mayo Clinic and Foundation, 200 First St SW, Rochester, MN 55905.

References 

  1. Venter DJ , Thomas DG . Multiple sequential molecular abnormalities in the evolution of human gliomas . Br J Cancer . 1991;63:753–757
  2. Liu W , James CD , Frederick L , et al.   PTEN/MMAC1 mutations and EGFR amplification in glioblastomas . Cancer Res . 1997;57:5254–5257
  3. Rasheed BK , Stenzel TT , McLendon RE , et al.   PTEN gene mutations are seen in high-grade but not in low-grade gliomas . Cancer Res . 1997;57:4187–4190
  4. Duerr EM , Rollbrocker B , Hayashi Y , et al.   PTEN mutations in gliomas and glioneuronal tumors . Oncogene . 1998;16:2259–2264
  5. Smith JS , Jenkins RB . Genetic alterations in adult diffuse glioma (Occurrence, significance, and prognostic implications) . Front Biosci . 2000;5:D213–D231
  6. von Deimling A , Fimmers R , Schmidt MC , et al.   Comprehensive allelotype and genetic anaysis of 466 human nervous system tumors . J Neuropathol Exp Neurol . 2000;59:544–558
  7. Ishii N , Maier D , Merlo A , et al.   Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines . Brain Pathol . 1999;9:469–479
  8. Chakravarti A , Delaney MA , Noll E , et al.   Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas . Clin Cancer Res . 2001;7:2387–2395
  9. Nister M , Libermann TA , Betsholtz C , et al.   Expression of messenger RNAs for platelet-derived growth factor and transforming growth factor-alpha and their receptors in human malignant glioma cell lines . Cancer Res . 1988;48:3910–3918
  10. Schlegel U , Moots PL , Rosenblum MK , et al.   Expression of transforming growth factor alpha in human gliomas . Oncogene . 1990;5:1839–1842
  11. Ekstrand AJ , James CD , Cavenee WK , et al.   Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo . Cancer Res . 1991;51:2164–2172
  12. Frederick L , Wang XY , Eley G , et al.   Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas . Cancer Res . 2000;60:1383–1387
  13. Smith JS , Tachibana I , Passe SM , et al.   PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme . J Natl Cancer Inst . 2001;93:1246–1256
  14. Libermann TA , Nusbaum HR , Razon N , et al.   Amplification and overexpression of the EGF receptor gene in primary human glioblastomas . J Cell Sci . 1985;3(suppl):161–172
  15. Lal A , Glazer CA , Martinson HM , et al.   Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion . Cancer Res . 2002;62:3335–3339
  16. Masui H , Kawamoto T , Sato JD , et al.   Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies . Cancer Res . 1984;44:1002–1007
  17. Sampson JH , Crotty LE , Lee S , et al.   Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors . Proc Natl Acad Sci USA . 2000;97:7503–7508
  18. Baselga J . Targeting the epidermal growth factor receptor (A clinical reality) . J Clin Oncol . 2001;19(suppl 18):41S–44S
  19. Brady LW , Miyamoto C , Woo DV , et al.   Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor (A phase II trial) . Int J Radiat Oncol Biol Phys . 1992;22:225–230
  20. Phillips PC , Levow C , Catterall M , et al.   Transforming growth factor-alpha-Pseudomonas exotoxin fusion protein (TGF-alpha-PE38) treatment of subcutaneous and intracranial human glioma and medulloblastoma xenografts in athymic mice . Cancer Res . 1994;54:1008–1015
  21. Lawrence DS , Niu J . Protein kinase inhibitors (The tyrosine-specific protein kinases) . Pharmacol Ther . 1998;77:81–8114
  22. Han Y , Caday CG , Nanda A , et al.   Tyrphostin AG 1478 preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors . Cancer Res . 1996;56:3859–3861
  23. Han Y , Caday CG , Umezawa K , et al.   Preferential inhibition of glioblastoma cells with wild-type epidermal growth factor receptors by a novel tyrosine kinase inhibitor ethyl-2,5- dihydroxycinnamate . Oncol Res . 1997;9:581–587
  24. Prados M , Chang S , Burton E , et al.   Phase I study of OSI-774 alone or with temozolomide in patients with malignant glioma . Proc Am Soc Clin Oncol . 2003;22:99; (abstr 394)
  25. Goldkorn T , Balaban N , Shannon M , et al.   EGF receptor phosphorylation is affected by ionizing radiation . Biochim Biophys Acta . 1997;1358:289–299
  26. Schmidt-Ullrich RK , Mikkelsen RB , Dent P , et al.   Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation . Oncogene . 1997;15:1191–1197
  27. Reardon DB , Contessa JN , Mikkelsen RB , et al.   Dominant negative EGFR-CD533 and inhibition of MAPK modify JNK1 activation and enhance radiation toxicity of human mammary carcinoma cells . Oncogene . 1999;18:4756–4766
  28. Cataldi A , Zauli G , Di Pietro R , et al.   Involvement of the pathway phosphatidylinositol-3-kinase/AKT-1 in the establishment of the survival response to ionizing radiation . Cell Signal . 2001;13:369–375
  29. Contessa JN , Reardon DB , Todd D , et al.   The inducible expression of dominant-negative epidermal growth factor receptor-CD533 results in radiosensitization of human mammary carcinoma cells . Clin Cancer Res . 1999;5:405–411
  30. Lammering G , Hewit TH , Hawkins WT , et al.   Epidermal growth factor receptor as a genetic therapy target for carcinoma cell radiosensitization . J Natl Cancer Inst . 2001;93:921–929
  31. Lammering G , Lin PS , Contessa JN , et al.   Adenovirus-mediated overexpression of dominant negative epidermal growth factor receptor-CD533 as a gene therapeutic approach radiosensitizes human carcinoma and malignant glioma cells . Int J Radiat Oncol Biol Phys . 2001;51:775–784
  32. Lammering G , Valerie K , Lin PS , et al.   Radiosensitization of malignant glioma cells through overexpression of dominant-negative epidermal growth factor receptor . Clin Cancer Res . 2001;7:682–690
  33. Balaban N , Moni J , Shannon M , et al.   The effect of ionizing radiation on signal transduction (Antibodies to EGF receptor sensitize A431 cells to radiation) . Biochim Biophys Acta . 1996;1314:147–156
  34. Bonner JA , Raisch KP , Trummell HQ , et al.   Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers . J Clin Oncol . 2000;18(suppl 21):47S–53S
  35. Huang SM , Harari PM . Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas (Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis) . Clin Cancer Res . 2000;6:2166–2174
  36. Milas L , Mason K , Hunter N , et al.   In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody . Clin Cancer Res . 2000;6:701–708
  37. Rao GS , Murray S , Ethier SP . Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor . Int J Radiat Oncol Biol Phys . 2000;48:1519–1528
  38. Barker 2nd FG , Simmons ML , Chang SM , et al.   EGFR overexpression and radiation response in glioblastoma multiforme . Int J Radiat Oncol Biol Phys . 2001;51:410–418
  39. Hermanson M , Funa K , Hartman M , et al.   Platelet-derived growth factor and its receptors in human glioma tissue (Expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops) . Cancer Res . 1992;52:3213–3219
  40. Heldin CH , Wasteson A , Westermark B . Growth of normal human glial cells in a defined medium containing platelet-derived growth factor . Proc Natl Acad Sci USA . 1980;77:6611–6615
  41. Potapova O , Fakhrai H , Baird S , et al.   Platelet-derived growth factor-B/v-sis confers a tumorigenic and metastatic phenotype to human T98G glioblastoma cells . Cancer Res . 1996;56:280–286
  42. Uhrbom L , Hesselager G , Nister M , et al.   Induction of brain tumors in mice using a recombinant platelet-derived growth factor B-chain retrovirus . Cancer Res . 1998;58:5275–5279
  43. Shamah SM , Stiles CD , Guha A . Dominant-negative mutants of platelet-derived growth factor revert the transformed phenotype of human astrocytoma cells . Mol Cell Biol . 1993;13:7203–7212
  44. Strawn LM , Mann E , Elliger SS , et al.   Inhibition of glioma cell growth by a truncated platelet-derived growth factor-beta receptor . J Biol Chem . 1994;269:21215–21222
  45. Vassbotn FS , Ostman A , Langeland N , et al.   Activated platelet-derived growth factor autocrine pathway drives the transformed phenotype of a human glioblastoma cell line . J Cell Physiol . 1994;158:381–389
  46. Kuratsu J , Ushio Y . Antiproliferative effect of trapidil, a platelet-derived growth factor antagonist, on a glioma cell line in vitro . J Neurosurg . 1990;73:436–440
  47. Buchdunger E , Zimmermann J , Mett H , et al.   Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative . Cancer Res . 1996;56:100–104
  48. Buchdunger E , Zimmermann J , Mett H , et al.   Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2- phenylaminopyrimidine class . Proc Natl Acad Sci USA . 1995;92:2558–2562
  49. Wen P , Yung W , Hess K , et al.   Phase I study of STI571 (Gleevec) for patients with recurrent malignant gliomas and meningiomas (NABTC 99–08) . Proc Am Soc Clin Oncol . 2002;21:73a; (abstr 288)
  50. Kilic T , Alberta JA , Zdunek PR , et al.   Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class . Cancer Res . 2000;60:5143–5150
  51. He J , Reifenberger G , Liu L , et al.   Analysis of glioma cell lines for amplification and overexpression of MDM2 . Genes Chromosomes Cancer . 1994;11:91–96
  52. Schiebe M , Ohneseit P , Hoffmann W , et al.   Analysis of mdm2 and p53 gene alterations in glioblastomas and its correlation with clinical factors . J Neurooncol . 2000;49:197–203
  53. Gomez-Manzano C , Fueyo J , Kyritsis AP , et al.   Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis . Cancer Res . 1996;56:694–699
  54. Dameron KM , Volpert OV , Tainsky MA , et al.   Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1 . Science . 1994;265:1582–1584
  55. Louis DN . The p53 gene and protein in human brain tumors . J Neuropathol Exp Neurol . 1994;53:11–21
  56. Van Meir EG , Polverini PJ , Chazin VR , et al.   Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells . Nat Genet . 1994;8:171–176
  57. McIlwrath AJ , Vasey PA , Ross GM , et al.   Cell cycle arrests and radiosensitivity of human tumor cell lines (Dependence on wild-type p53 for radiosensitivity) . Cancer Res . 1994;54:3718–3722
  58. Haas-Kogan DA , Kogan SS , Yount G , et al.   p53 function influences the effect of fractionated radiotherapy on glioblastoma tumors . Int J Radiat Oncol Biol Phys . 1999;43:399–403
  59. Lee JM , Bernstein A . p53 mutations increase resistance to ionizing radiation . Proc Natl Acad Sci USA . 1993;90:5742–5746
  60. Slichenmyer WJ , Nelson WG , Slebos RJ , et al.   Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage . Cancer Res . 1993;53:4164–4168
  61. Westermark B , Heldin CH , Nister M . Platelet-derived growth factor in human glioma . Glia . 1995;15:257–263
  62. Prigent SA , Nagane M , Lin H , et al.   Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway . J Biol Chem . 1996;271:25639–25645
  63. Guha A , Feldkamp MM , Lau N , et al.   Proliferation of human malignant astrocytomas is dependent on Ras activation . Oncogene . 1997;15:2755–2765
  64. Yang BC , Wang YS , Liu HS , et al.   Ras signaling is involved in the expression of Fas-L in glioma . Lab Invest . 2000;80:529–537
  65. Hahne M , Rimoldi D , Schroter M , et al.   Melanoma cell expression of Fas(Apo-1/CD95) ligand (Implications for tumor immune escape) . Science . 1996;274:1363–1366
  66. Strand S , Hofmann WJ , Hug H , et al.   Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells—A mechanism of immune evasion? . Nat Med . 1996;2:1361–1366
  67. Rait A , Pirollo K , Will DW , et al.   3′-End conjugates of minimally phosphorothioate-protected oligonucleotides with 1-O-hexadecylglycerol (Synthesis and anti-ras activity in radiation-resistant cells) . Bioconjug Chem . 2000;11:153–160
  68. Rudin CM , Holmlund J , Fleming GF , et al.   Phase I trial of ISIS 5132, an antisense oligonucleotide inhibitor of c- raf-1, administered by 24-hour weekly infusion to patients with advanced cancer . Clin Cancer Res . 2001;7:1214–1220
  69. Lerner EC , Qian Y , Blaskovich MA , et al.   Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes . J Biol Chem . 1995;270:26802–26806
  70. Lerner EC , Hamilton AD , Sebti SM . Inhibition of Ras prenylation (A signaling target for novel anti-cancer drug design) . Anticancer Drug Des . 1997;12:229–238
  71. Sebti SM , Hamilton AD . Inhibition of Ras prenylation (A novel approach to cancer chemotherapy) . Pharmacol Ther . 1997;74:103–114
  72. Monia BP , Johnston JF , Geiger T , et al.   Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase . Nat Med . 1996;2:668–675
  73. Monia BP , Sasmor H , Johnston JF , et al.   Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo . Proc Natl Acad Sci USA . 1996;93:15481–15484
  74. Schulte TW , Blagosklonny MV , Romanova L , et al.   Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf- 1-MEK-mitogen-activated protein kinase signalling pathway . Mol Cell Biol . 1996;16:5839–5845
  75. Adjei AA . Ras signaling pathway proteins as therapeutic targets . Curr Pharm Des . 2001;7:1581–1594
  76. Glass TL , Liu TJ , Yung WK . Inhibition of cell growth in human glioblastoma cell lines by farnesyltransferase inhibitor SCH66336 . Neurooncology . 2000;2:151–158
  77. Bouterfa HL , Sattelmeyer V , Czub S , et al.   Inhibition of Ras farnesylation by lovastatin leads to downregulation of proliferation and migration in primary cultured human glioblastoma cells . Anticancer Res . 2000;20:2761–2771
  78. Bernhard EJ , Stanbridge EJ , Gupta S , et al.   Direct evidence for the contribution of activated N-ras and K-ras oncogenes to increased intrinsic radiation resistance in human tumor cell lines . Cancer Res . 2000;60:6597–6600
  79. Gupta AK , Bakanauskas VJ , Cerniglia GJ , et al.   The Ras radiation resistance pathway . Cancer Res . 2001;61:4278–4282
  80. Gupta AK , Bakanauskas VJ , McKenna WG , et al.   Ras regulation of radioresistance in cell culture . Methods Enzymol . 2001;333:284–290
  81. Ling CC , Endlich B . Radioresistance induced by oncogenic transformation . Radiat Res . 1989;120:267–279
  82. McKenna WG , Weiss MC , Bakanauskas VJ , et al.   The role of the H-ras oncogene in radiation resistance and metastasis . Int J Radiat Oncol Biol Phys . 1990;18:849–859
  83. Miller AC , Gafner J , Clark EP , et al.   Differences in radiation-induced micronuclei yields of human cells (Influence of ras gene expression and protein localization) . Int J Radiat Biol . 1993;64:547–554
  84. Bernhard EJ , McKenna WG , Hamilton AD , et al.   Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes . Cancer Res . 1998;58:1754–1761
  85. Ueki K , Fruman DA , Brachmann SM , et al.   Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signaling and survival . Mol Cell Biol . 2002;22:965–977
  86. Tamura M , Gu J , Matsumoto K , et al.   Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN . Science . 1998;280:1614–1617
  87. Gu J , Tamura M , Pankov R , et al.   Shc and FAK differentially regulate cell motility and directionality modulated by PTEN . J Cell Biol . 1999;146:389–403
  88. Li DM , Sun H . PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells . Proc Natl Acad Sci USA . 1998;95:15406–15411
  89. Wen S , Stolarov J , Myers MP , et al.   PTEN controls tumor-induced angiogenesis . Proc Natl Acad Sci USA . 2001;98:4622–4627
  90. Gingras AC , Kennedy SG , O’Leary MA , et al.   4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway . Genes Dev . 1998;12:502–513
  91. Wu X , Senechal K , Neshat MS , et al.   The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway . Proc Natl Acad Sci USA . 1998;95:15587–15591
  92. da Rocha AB , Mans DR , Regner A , et al.   Targeting protein kinase C (New therapeutic opportunities against high- grade malignant gliomas?) . Oncologist . 2002;7:17–33
  93. Hosoi H , Dilling MB , Liu LN , et al.   Studies on the mechanism of resistance to rapamycin in human cancer cells . Mol Pharmacol . 1998;54:815–824
  94. Geoerger B , Kerr K , Tang CB , et al.   Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy . Cancer Res . 2001;61:1527–1532
  95. Lin H , Bondy ML , Langford LA , et al.   Allelic deletion analyses of MMAC/PTEN and DMBT1 loci in gliomas (Relationship to prognostic significance) . Clin Cancer Res . 1998;4:2447–2454
  96. Raffel C , Frederick L , O’Fallon JR , et al.   Analysis of oncogene and tumor suppressor gene alterations in pediatric malignant astrocytomas reveals reduced survival for patients with PTEN mutations . Clin Cancer Res . 1999;5:4085–4090
  97. Sano T , Lin H , Chen X , et al.   Differential expression of MMAC/PTEN in glioblastoma multiforme (Relationship to localization and prognosis) . Cancer Res . 1999;59:1820–1824
  98. Cheng SY , Huang HJ , Nagane M , et al.   Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor . Proc Natl Acad Sci USA . 1996;93:8502–8507
  99. Gollmer JCLA , Gioanni J . Expression of vascular endothelial growth factor-b in human astrocytoma . Neurooncology . 2000;22:80–86
  100. Yao Y , Kubota T , Sato K , et al.   Prognostic value of vascular endothelial growth factor and its receptors Flt-1 and Flk-1 in astrocytic tumours . Acta Neurochir . 2001;143:159–166
  101. Varlet P , Guillamo JS , Nataf F , et al.   Vascular endothelial growth factor expression in oligodendrogliomas (A correlative study with Sainte-Anne malignancy grade, growth fraction and patient survival) . Neuropathol Appl Neurobiol . 2000;26:379–389
  102. Millauer B , Shawver LK , Plate KH , et al.   Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant . Nature . 1994;367:576–579
  103. Tanaka T , Cao Y , Folkman J , et al.   Viral vector-targeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA . Cancer Res . 1998;58:3362–3369
  104. Griscelli F , Li H , Cheong C , et al.   Combined effects of radiotherapy and angiostatin gene therapy in glioma tumor model . Proc Natl Acad Sci USA . 2000;97:6698–6703
  105. Fine HA , Wen PY , Maher EA , et al.   Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas . J Clin Oncol . 2003;21:2299–2304
  106. Jeuken JW , Sprenger SH , Wesseling P , et al.   Identification of subgroups of high-grade oligodendroglial tumors by comparative genomic hybridization . J Neuropathol Exp Neurol . 1999;58:606–612
  107. Kraus JA , Koopmann J , Kaskel P , et al.   Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma . J Neuropathol Exp Neurol . 1995;54:91–95
  108. Bello MJ , Leone PE , Vaquero J , et al.   Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors . Int J Cancer . 1995;64:207–210
  109. Cairncross JG , Ueki K , Zlatescu MC , et al.   Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas . J Natl Cancer Inst . 1998;90:1473–1479
  110. Ohgaki H , Eibl RH , Wiestler OD , et al.   p53 mutations in nonastrocytic human brain tumors . Cancer Res . 1991;51:6202–6205
  111. Reifenberger J , Reifenberger G , Liu L , et al.   Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p . Am J Pathol . 1994;145:1175–1190
  112. Maintz D , Fiedler K , Koopmann J , et al.   Molecular genetic evidence for subtypes of oligoastrocytomas . J Neuropathol Exp Neurol . 1997;56:1098–1104
  113. Hagel C , Laking G , Laas R , et al.   Demonstration of p53 protein and TP53 gene mutations in oligodendrogliomas . Eur J Cancer . 1996;32A:2242–2248
  114. Kros JM , Godschalk JJ , Krishnadath KK , et al.   Expression of p53 in oligodendrogliomas . J Pathol . 1993;171:285–290
  115. Fuller GN , Hess KR , Rhee CH , et al.   Molecular classification of human diffuse gliomas by multidimensional scaling analysis of gene expression profiles parallels morphology-based classification, correlates with survival, and reveals clinically-relevant novel glioma subsets . Brain Pathol . 2002;12:108–116
  116. Fan Z , Baselga J , Masui H , et al.   Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts . Cancer Res . 1993;53:4637–4642
  117. Ciardiello F , Caputo R , Pomatico G , et al.   Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A . Int J Cancer . 2000;85:710–715
  118. Inoue K , Slaton JW , Perrotte P , et al.   Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma . Clin Cancer Res . 2000;6:4874–4884
  119. Sirotnak FM , Zakowski MF , Miller VA , et al.   Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase . Clin Cancer Res . 2000;6:4885–4892
  120. Erlichman C , Boerner SA , Hallgren CG , et al.   The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7- ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux . Cancer Res . 2001;61:739–748
  121. Nagane M , Levitzki A , Gazit A , et al.   Drug resistance of human glioblastoma cells conferred by a tumor- specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases . Proc Natl Acad Sci USA . 1998;95:5724–5729
  122. Chakravarti A , Loeffler JS , Dyson NJ . Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling . Cancer Res . 2002;62:200–207
  123. Hu L , Hofmann J , Lu Y , et al.   Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models . Cancer Res . 2002;62:1087–1092

 Supported in part by the American Brain Tumor Association (ABTA)/Joel A. Gingras, Jr Fellowship.

PII: S0093-7754(04)00324-0

doi: 10.1053/j.seminoncol.2004.07.002

Seminars in Oncology
Volume 31, Issue 5 , Pages 595-604 , October 2004

Article Tools

* Image Usage & Resolution